ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Overview of attention for article published in Biology of Blood & Marrow Transplantation, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#8 of 3,687)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 9 news outlets
blogs: 2 blogs
policy: 2 policy sources
twitter: 99 X users
patent: 149 patents

wikipedia: 1 Wikipedia page
reddit: 3 Redditors
video: 1 YouTube creator
guideline: 7 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 1833 Mendeley

So far, Altmetric has seen 18 news stories from 9 outlets.

Rx Road Map: Lisocabtagene Maraleucel in Follicular Lymphoma

Oncology Nursing News, 05 Jan 2026

For Which Patients With Follicular Lymphoma is Lisocabtagene Maraleucel Approved? On May 15, 2024, the FDA approved…

Rx Road Map: Lisocabtagene Maraleucel for Mantle Cell Lymphoma

Oncology Nursing News, 20 Sep 2025

Whom Is This Drug Approved for? Lisocabtagene maraleucel (Breyanzi; liso-cel) CAR T-cell therapy is indicated for the treatment…

CAR T Cell Therapy for Glioblastoma: Phase 1 Trial Results

Time.News, 01 Jun 2025

Price, M. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United…

CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies

OncLive, 09 Apr 2025

Zhubin Gahvari, MD, MS There are still no FDA-approved autologous chimeric antigen receptor (CAR) T-cell therapies available…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 14 additional news stories.